CorMedix Inc
CRMD16.560USD
+2.950+21.68%
收盤 06/23, 16:00（美東）報價延遲15分鐘
1.12B總市值
虧損本益比TTM
關於 CorMedix Inc 公司
CorMedix Inc. 是一家生物製藥公司。該公司專注於開發和商業化用於預防和治療危及生命的病症和疾病的治療產品。該公司專注於商業化其主打產品 DefenCath，這是一種抗菌導管鎖定溶液，經批准用於降低通過中央靜脈導管接受慢性血液透析的腎衰竭成年患者的導管相關血流感染髮生率。DefenCath 是一種由 13.5 mg/mL 牛磺羅定和 1000 USP 單位/mL 肝素組成的配方，用於降低通過中央靜脈導管 (CVC) 接受慢性血液透析的腎衰竭成年患者的導管相關血流感染 (CRBSI) 發生率。除了 DefenCath 之外，該公司還贊助了一項臨牀前研究合作，以研究牛磺羅定作爲罕見兒科腫瘤的潛在治療方法。
公司簡介
公司代碼CRMD
公司名稱CorMedix Inc
上市日期Mar 25, 2010
成立日期2006
CEOMr. Joseph Todisco
員工數量64
證券類型Ordinary Share
年結日Mar 25
公司地址300 Connell Drive
城市BERKELEY HEIGHTS
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編07922
電話19085179500
網址https://cormedix.com/
公司代碼CRMD
上市日期Mar 25, 2010
成立日期2006
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Executive Vice President, Chief Clinical Strategy and Operations Officer
Executive Vice President, Chief Clinical Strategy and Operations Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ms. Beth Zelnick Kaufman
Ms. Beth Zelnick Kaufman
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
Executive Vice President, Chief Legal and Compliance Officer, Corporate Secretary
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Joseph Todisco
Mr. Joseph Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
323.43K
-2.01%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-3.77%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
53.47K
-31.86%
Ms. Erin Mistry
Ms. Erin Mistry
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
29.12K
-54.14%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
11.00K
-69.44%
Mr. Dan Ferry
Mr. Dan Ferry
IR Contact Officer
IR Contact Officer
--
--
收入明細
FY2024
暫無數據
地區USD
名稱
營收
佔比
United States
43.47M
0.00%
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
持股股東
持股股東
佔比
BlackRock Institutional Trust Company, N.A.
6.35%
The Vanguard Group, Inc.
5.36%
Elliott Management Corporation
3.60%
State Street Global Advisors (US)
2.27%
Geode Capital Management, L.L.C.
2.11%
Other
80.30%
股東類型
持股股東
佔比
Investment Advisor
13.86%
Investment Advisor/Hedge Fund
13.60%
Hedge Fund
5.69%
Research Firm
1.60%
Sovereign Wealth Fund
1.39%
Individual Investor
1.19%
Pension Fund
0.45%
Bank and Trust
0.30%
Venture Capital
0.06%
Other
61.88%
機構持股
更新時間: 2月24日 週一
更新時間: 2月24日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
262
29.51M
43.73%
+3.54M
2024Q4
252
24.74M
40.82%
-30.08K
2024Q3
228
19.79M
34.25%
-1.78M
2024Q2
217
17.74M
32.28%
-4.09M
2024Q1
218
17.92M
32.60%
-5.73M
2023Q4
217
19.38M
35.35%
-2.82M
2023Q3
208
18.46M
33.68%
-3.54M
2023Q2
197
19.74M
38.10%
+6.18M
2023Q1
190
11.28M
25.34%
-2.76M
2022Q4
191
11.93M
28.90%
-1.83M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
BlackRock Institutional Trust Company, N.A.
4.20M
6.44%
+868.26K
+26.06%
Dec 31, 2024
The Vanguard Group, Inc.
3.38M
5.18%
+309.51K
+10.09%
Dec 31, 2024
Elliott Management Corporation
2.87M
4.4%
+1.32M
+85.14%
Dec 31, 2024
State Street Global Advisors (US)
1.45M
2.23%
+227.39K
+18.55%
Dec 31, 2024
Geode Capital Management, L.L.C.
1.39M
2.14%
+108.36K
+8.44%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
940.59K
1.44%
+940.59K
--
Dec 31, 2024
UBS Financial Services, Inc.
379.87K
0.58%
+340.35K
+861.30%
Dec 31, 2024
Morgan Stanley & Co. LLC
283.12K
0.43%
+50.06K
+21.48%
Dec 31, 2024
Northern Trust Investments, Inc.
510.89K
0.78%
+100.11K
+24.37%
Dec 31, 2024
查看更多
持股ETF
更新時間: 6月6日 週五
更新時間: 6月6日 週五
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
0.49%
First Trust Active Factor Small Cap ETF
0.17%
iShares Micro-Cap ETF
0.13%
Vanguard US Momentum Factor ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares Biotechnology ETF
0.07%
ProShares Ultra Nasdaq Biotechnology
0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.37%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比0.72%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.49%
First Trust Active Factor Small Cap ETF
佔比0.17%
iShares Micro-Cap ETF
佔比0.13%
Vanguard US Momentum Factor ETF
佔比0.1%
Invesco Nasdaq Biotechnology ETF
佔比0.08%
iShares Biotechnology ETF
佔比0.07%
ProShares Ultra Nasdaq Biotechnology
佔比0.07%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.06%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
